UroGen Pharma Ltd. beats earnings expectations. Reported EPS is $-0.47, expectations were $-0.48244. Operator: Good day, and thank you for standing by. Welcome to the UroGen Pharma Q1 2026 Results ...
enGene (NASDAQ:ENGN) reported preliminary data from the pivotal Cohort 1 of its ongoing Phase 2 LEGEND trial evaluating ...
Cash and cash equivalents of $10.2 million as of March 31, 2026 Favorable efficacy and safety reported in a small sample of triple negative breast cancer ("TNBC") ...
Bristol Myers Squibb today announced that the European Commission has granted approval to Sotyktu (deucravacitinib), alone or in combination with methotrexate, for the treatment of active psoriatic ...
Expert run coaches explain the benefits of treadmill runs, how to make them fun, and provide three treadmill workouts that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results